Organs-on-Chips Market Size, Share & Growth Trend Analysis Report (2026 - 2035)

Market Outlook

The global organs-on-chips market, valued at USD 100 million in 2025, is projected to reach USD 129 million in 2026 and USD 944 million by 2035, representing a CAGR of 24.8% during the forecast period 2026-2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of product, organ-based models hold the highest share, capturing ~75% of the current market.
• Based on the type of organ, organ-on-chip products account for the largest share of the current market.
• With respect to the type of single organ-based model, liver-on-a-chip models capture the largest share of the current market.
• By type of material, polydimethylsiloxane accounts for the majority share of the current market.
• Based on purpose, research subsegment dominates the market, accounting for >50% of the overall share.
• With respect to application area, cancer research captures the largest share of the current market.
• In terms of end-user, pharmaceutical and biotech companies hold the highest share of the current market.
• In terms of geographical regions, North America currently holds the highest share, accounting for ~45% of the overall market.

Key Market Statistics

• Market Size in 2026: USD 129 Million
• Estimated Market Size in 2035: USD 944 Million
• CAGR (2026-2035): 24.8%
• North America: Largest market in 2026
• Europe: Fastest growing region

Market Introduction

Drug development continues to face a persistent translation gap between preclinical success and clinical performance. In the US, only a small fraction of potential drug candidates advances from preclinical testing into clinical trials. Moreover, a large proportion of those that enter human studies ultimately fail, primarily due to insufficient efficacy or unexpected toxicity. One of the key reasons for this high attrition is the limited ability of conventional animal-based models to accurately replicate human biology, disease complexity, and organ-level responses.

Organs-on-chips technology has emerged as one of the most promising solutions to address this challenge. These microfluidic systems use living human cells to recreate key structural, mechanical, and functional features of human organs in a controlled in vitro environment. By simulating tissue-tissue interactions, fluid flow, concentration gradients, and dynamic mechanical forces, organ-on-chip platforms can offer a more physiologically relevant view of how drug candidates may behave in the human body.

This technological advancement also aligns with the broader industry transition toward ethical, sustainable, and human-relevant testing approaches. Pharmaceutical manufacturers, biotechnology companies, CROs, and academic institutions are increasingly using advanced in vitro models to complement or, in selected cases, reduce dependence on animal testing. Further, this shift is reinforced by regulatory initiatives supporting New Approach Methodologies (NAMs). For instance, the US Food and Drug Administration (FDA) has increasingly incorporated NAMs into regulatory science through initiatives such as its Alternative Methods Working Group and guidance encouraging the use of scientifically validated non-animal approaches where appropriate. Similarly, the US Environmental Protection Agency (EPA) continues to promote the development and application of NAMs to modernize chemical safety assessments while reducing dependence on animal testing. Collectively, these initiatives are expected to strengthen regulatory confidence in human-relevant testing platforms, thereby expanding the role of organ-on-chip technologies in preclinical research and translational drug development.

In response to these technological and regulatory developments, organs-on-chips technology developers, microfluidics companies, and life science tool providers are investing in proprietary organ-on-chip platforms, disease-specific models, and specialized testing services to support early-stage drug discovery and preclinical evaluation. Continuous innovation in platform design, cell sourcing, and multi-organ integration is expected to further enhance the predictive capabilities and commercial adoption of these systems across pharmaceutical and biotechnology research.

Leading Companies in the Organs-on-Chips Market

Abbreviation: YoE: Year of Establishment

Market Segmentation

Based on the research, we have segmented the Organs-on-Chips Market into type of product, type of organ, type of single organ-based model, type of material, purpose, application area, end user, geographical regions and leading players.

By Type of Product

• Organ-based
• Disease-based

By Type of Organ

• Single Organ-based
• Multi Organ-based

By Type of Single Organ-based Model

• Liver
• Lung
• Brain
• Heart
• Intestine
• Kidney
• Other Organs

By Type of Material

• Polydimethylsiloxane
• Polymer
• Glass
• Others

By Purpose

• Research Purposes
• Therapeutic Purposes

By Application Area

• Drug Discovery / Toxicity Testing
• Cancer Research
• Stem Cell Research
• Tissue Engineering / Regenerative Medicine

By End User

• Pharmaceutical and Biotech Companies
• Academic and Research Players
• Cosmetic Industry Players
• Other End Users

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

Organs-on-Chips Market Key Insights

What are the Key Drivers of Growth in the Organs-on-Chips Market?

• Rising Need to Reduce Drug Development Failure Rates: A major driver for the organs-on-chips market is the pharmaceutical industry's need to improve the predictability of preclinical testing. A large share of drug candidates still fail during clinical development, mainly due to lack of efficacy or safety-related issues, creating significant financial and time losses for drug developers. Organs-on-chips can help address this gap by using human cells and organ-like microenvironments to generate more clinically relevant data before drugs enter human trials.
• Growing Shift Away from Animal-Based Testing: The organ-on-chips market is also being driven by the global shift toward non-animal and human-relevant testing models. Traditional animal models often fail to fully replicate human physiology, metabolism, immune response, and organ-specific toxicity. Organs-on-chips offer an alternative by recreating human tissue-level functions in microfluidic systems, making them valuable for safety pharmacology, toxicity testing, and disease modeling. In April 2025, the FDA announced a plan to reduce, refine, or potentially replace animal testing requirements for monoclonal antibodies and other drugs using New Approach Methodologies, including organoid and organ-like laboratory models.

What are the Main Challenges for Market Growth?

• Limited Standardization Across Platforms: One of the biggest challenges for the organs-on-chips market is the lack of standardized device design, materials, cell sources, culture conditions, sampling protocols, and readout methods. Different companies and laboratories often use different chip formats, organ models, flow conditions, and analytical endpoints, making it difficult to compare results across platforms. This limits broader pharmaceutical adoption because drug developers and regulators require reproducible and comparable data before relying on these systems for decision-making.
• Limited Availability of High-Quality Human Cells: The performance of organ-on-chip models depends heavily on the quality, maturity, and consistency of the cells used. Access to reliable human primary cells, disease-specific cells, or patient-derived stem-cell models can be limited, costly, and variable across donors. Immature stem-cell-derived cells may also fail to fully replicate adult tissue function, which can affect the biological relevance of the model and create uncertainty around translational accuracy.

Recent Developments in Organs-on-Chips Market

• In May 2026, Critical Path Institute launched the NAMs Developer Coalition, bringing together developers such as CN Bio, Curi Bio, Emulate, and InSphero to advance validation and qualification of human-relevant methods, including organ chips and microphysiological systems. The coalition is designed to support regulatory readiness across defined contexts of use.
• In April 2026, the Wyss Institute reported that Organ Chip AVATAR models made with cells from NASA Artemis II astronauts were used to study human tissue responses to deep-space stressors. The project extends organ-chip use into personalized space-health research and countermeasure development.
• In January 2026, CN Bio announced that it joined a 3Rs Collaborative project with FDA CDER, NIH NICEATM, C-Path and commercial developers to evaluate liver MPS platforms for drug-induced liver injury prediction after the project was accepted into FDA's ISTAND program. The effort targets regulatory confidence in liver-on-chip assays.

Industry Experts on the Organs-on-Chips Market

Driven by advances in microphysiological system engineering and increasing adoption of human-relevant disease models, the organs-on-chips market is entering a new expansion phase beyond single-tissue platforms.

Emphasizing this shift, Andries van der Meer (Professor, University of Twente), stated, "Organ-on-Chip technology offers a solution by mimicking the complexity of the human body in a controlled laboratory environment. This makes it possible to study human responses more accurately. The technology is cost- and time-efficient and can be optimized for future generations of models."

Discussions with multiple stakeholders in this domain have influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Chief Executive Officer, Small Company, US
• Chief Executive Officer, Mid-sized Company, France
• Chief Executive Officer, Small Company, South Korea
• Chief Executive Officer, Small Company, Italy
• Chief Executive Officer, Small Company, Scotland
• Chief Technology Officer, Mid-sized Company, The Netherlands
• Chief Business Development Officer, Mid-sized Company, France
• President, Mid-sized Company, US

In addition, the market report includes transcripts of the following third-party discussions:

• Founder and Chief Executive Officer, Mid-sized Company, Germany
• Founder / Chief Scientist, Small Company, Italy
• Chief Scientific Officer, Mid-sized Company, US
• Chief Scientific Officer, Mid-sized Company, US
• Chief Scientific Officer, Mid-sized Company, US
• Chief Scientific Officer, Mid-sized Company, US
• Founding Director, Mid-sized Company, US
• Professor of Biomedical Engineering, Large Company, UK
• Professor, Very Large Company, Netherlands
• Postdoctoral Researcher, Large Company, US

Market Share Insights

Which Type of Product Accounts for the Largest Share of the Overall Market?

Based on the type of product, the global organs-on-chips market is segmented into Organ-based and Disease-based.

Currently, organ-based models account for the largest share of the overall organ-on-chips market, capturing ~75% share. This is because of their extensive use in drug discovery, toxicity testing, disease modeling, and preclinical research. These models accurately replicate the structural architecture, physiological functions, and microenvironment of individual human organs, enabling researchers to generate more predictive human-relevant data than conventional in vitro cell culture and animal models.

Furthermore, regulatory agencies and pharmaceutical companies are increasingly adopting organ-specific microphysiological systems to improve preclinical decision-making and reduce late-stage drug attrition. For example, Emulate has commercialized liver-, lung-, intestine-, and kidney-on-chip platforms that are widely used by pharmaceutical companies for safety assessment and drug development. Additionally, MIMETAS also offers organ-specific tissue models for preclinical screening. The maturity of these platforms, combined with their broad applicability across multiple therapeutic areas have reinforced the dominance of the organ-based models.

The disease-based models segment is likely to grow at a significant pace during the forecast period due to the pharmaceutical industry's increasing emphasis on disease-specific drug discovery and precision medicine. Drug developers are shifting from evaluating compounds in healthy tissue models to disease-relevant microphysiological systems that better replicate pathological conditions such as cancer, metabolic disorders, neurodegenerative diseases, fibrosis, and inflammatory diseases.

Which Type of Organ Accounts for the Largest Share of the Organs-on-Chips Market?

Based on the type of organ, the global organs-on-chips market is segmented into single organ-based and multi organ-based.

Currently, single organ-based models account for the largest share of the global organ-on-chips market. This dominance is primarily due to their higher level of technological maturity, broader commercial availability, and widespread adoption in pharmaceutical preclinical workflows. Most drug candidates undergo organ-specific evaluations, particularly for liver metabolism, cardiotoxicity, nephrotoxicity, pulmonary toxicity, and intestinal absorption, before advancing to clinical development. As a result, pharmaceutical and biotechnology companies routinely invest in validated single-organ platforms that can be easily incorporated into existing ADME toxicology testing, and efficacy and safety testing pipelines.

Moreover, regulatory agencies and industry consortia have generated substantially more validation data for single-organ systems than for interconnected multi-organ platforms, increasing industry confidence in their use. For example, AlveoliX, BiomimX and React4Life provide commercially available organ-specific platforms spanning lungs, heart, gut, liver, skin, and joint models for drug efficacy, metabolism, safety and toxicity studies. Their focused biological scope, standardized experimental workflows, and comparatively lower implementation complexity have supported the continued dominance of the single-organ models segment.

The multi-organ models segment is likely to grow at a significant pace during the forecast period owing to the increasing demand for physiologically integrated human models capable of predicting whole-body drug responses. Notably, multi-organ platforms enable researchers to study how drugs are metabolized in one organ and subsequently affect others, providing insights that cannot be obtained using isolated organ models. Furthermore, growing collaborations between pharmaceutical companies, regulatory agencies, and organ-on-chip developers to reduce animal testing and improve prediction of human clinical outcomes are expected to drive robust growth of the multi-organ models segment during the forecast period.

Which Purpose Leads the Organs-on-Chips Market?

Based on purpose, the organs-on-chips market is segmented into research purposes and therapeutic purposes.

Research purposes hold the largest share of the organs-on-chips market owing to the extensive adoption of organ-on-chip platforms during the early stages of drug discovery, target identification, disease mechanism studies, and preclinical safety assessment. Pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations (CROs) increasingly utilize these platforms to generate human-relevant data before progressing drug candidates to animal studies or clinical trials, thereby improving decision-making and reducing late-stage attrition. Moreover, substantial public and private funding for biomedical research, coupled with growing collaborations between industry and academia, has accelerated the adoption of organ-on-chip technologies for fundamental and translational research.

For example, Emulate has partnered with leading pharmaceutical companies and research institutions to integrate organ-on-chip platforms into drug discovery and toxicology studies, while initiatives supported by organizations such as the National Institutes of Health have further expanded their use in biomedical research. The large volume of research activities compared to commercial therapeutic applications has reinforced the dominance of the research purposes segment.

The therapeutic purpose segment is likely to grow at a significant pace during the forecast period owing to the increasing integration of organ-on-chip technologies into precision medicine and patient-specific therapeutic development. Pharmaceutical companies are increasingly employing patient-derived organ-on-chip models to predict drug efficacy, optimize dosing strategies, and evaluate personalized treatment responses before clinical administration. Additionally, growing investments in cell and gene therapies, biologics, immunotherapies, and regenerative medicine are driving demand for physiologically relevant platforms that can better predict therapeutic outcomes than conventional preclinical models.

Which Application Area Accounts for the Largest Share of the Organs-on-Chips Market?

Based on application area, the global organs-on-chips market is segmented into drug discovery / toxicity testing, cancer research, stem cell research and tissue engineering / regenerative medicine.

Currently, cancer research holds the largest share of the organs-on-chips market owing to the substantial global investment in oncology drug development and the high attrition rates associated with cancer therapeutics during clinical trials. Oncology accounts for the largest proportion of pharmaceutical R&D pipelines, prompting drug developers to increasingly adopt organ-on-chip platforms to improve the predictive accuracy of preclinical efficacy and toxicity studies before advancing candidates into costly cancer-related clinical trials. Moreover, the rapid expansion of immuno-oncology, antibody-drug conjugates (ADCs), cell and gene therapies, and targeted therapies have increased the demand for physiologically relevant tumor models capable of evaluating complex tumor biology and therapeutic responses.

Further, the cancer research segment is likely to grow at a significant pace during the forecast period owing to the increasing complexity of next-generation oncology therapeutics pipeline and the growing need for human-relevant preclinical models to accelerate drug development.

Regional Analysis: Which Regions are Showing the Fastest Growth in Organs-on-Chips Market?

In terms of geographical regions, the global organs-on-chips market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.

North America Market: Largest Regional Market

Currently, North America accounts for the largest share of the organ-on-chips market. This dominance is due to its well-established biopharmaceutical industry, substantial investment in biomedical research, and early adoption of advanced preclinical technologies.

Moreover, the region is home to several leading organ-on-chip developers, including Emulate, CN Bio (U.S. operations), and numerous biotechnology startups that collaborate extensively with global pharmaceutical companies to accelerate drug discovery and toxicology studies. Major pharmaceutical companies such as Pfizer, Merck & Co., and Johnson & Johnson have also increasingly incorporated organ-on-chip platforms into preclinical R&D to improve the prediction of human drug responses and reduce late-stage clinical failures.

Europe: Fastest-Growing Region

The Europe organs-on-chips market is likely to grow at a significant pace during the forecast period owing to increasing regulatory support for alternatives to animal testing, expanding public funding for advanced in vitro technologies, and growing collaborations between academia, biotechnology companies, and pharmaceutical manufacturers.

The region has witnessed strong momentum following the European Union's continued commitment to reducing animal experimentation and promoting New Approach Methodologies, encouraging greater adoption of organ-on-chip platforms in drug development and safety assessment. In addition, Europe is home to leading organ-on-chip innovators such as MIMETAS, TissUse, and InSphero, which continue to expand partnerships with pharmaceutical companies and research institutions.

Scope of Organs-on-Chips Market Report